Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G4OD
|
|||
| Former ID |
DAP000880
|
|||
| Drug Name |
Tigecycline
|
|||
| Synonyms |
Tigilcycline; Tygacil; Tigecycline [USAN]; GAR 936; GAR-936; TBG-MINO; Tygacil (TN); Tygacil(TM); GAR-936,Tigecycline; Tigecycline (JAN/USAN); WAY-GAR-936; Tygacil, GAR-936, WAY-GAR-936, TBG-MINO, Tigecycline; N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide; (4S,12aS)-4,7-Bis(dimethylamino)-9-{2-[(tert-butyl)amino]acetylamino}-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide; (4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; (4S,4aS,5aR,12aS)-9-[(N-tert-butylglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 9-t-Butylglycylamido minocycline
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Skin infection [ICD-11: 1F28-1G0Z; ICD-10: L00-L99; ICD-9: 680-709] | Approved | [1], [2], [3] | |
| Therapeutic Class |
Antibiotics
|
|||
| Company |
Wyeth Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H39N5O8
|
|||
| Canonical SMILES |
CC(C)(C)NCC(=O)NC1=CC(=C2CC3CC4C(C(=O)C(=C(C4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C
|
|||
| InChI |
1S/C29H39N5O8/c1-28(2,3)31-11-17(35)32-15-10-16(33(4)5)13-8-12-9-14-21(34(6)7)24(38)20(27(30)41)26(40)29(14,42)25(39)18(12)23(37)19(13)22(15)36/h10,12,14,21,31,36-37,40,42H,8-9,11H2,1-7H3,(H2,30,41)(H,32,35)/t12-,14-,21-,29-/m0/s1
|
|||
| InChIKey |
SOVUOXKZCCAWOJ-HJYUBDRYSA-N
|
|||
| CAS Number |
CAS 220620-09-7
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:149836
|
|||
| ADReCS Drug ID | BADD_D02217 | |||
| SuperDrug ATC ID |
J01AA12
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bacteroides was not significantly changed by Tigecycline. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bifidobacterium was decreased by Tigecycline (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Enterobacter
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterobacter was increased by Tigecycline. | |||
|
Studied Microbe: Enterobacteriaceae
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterobacteriaceae was increased by Tigecycline. | |||
|
Studied Microbe: Enterobacteriaceae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterobacteriaceae was not significantly changed by Tigecycline. | |||
|
Studied Microbe: Enterobacteriaceae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterobacteriaceae was not significantly changed by Tigecycline. | |||
|
Studied Microbe: Escherichia
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Escherichia was decreased by Tigecycline (p < 0.05). | |||
|
Studied Microbe: Klebsiella
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Klebsiella was increased by Tigecycline. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Clostridium
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Clostridium was not significantly changed by Tigecycline. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterococcus was decreased by Tigecycline (p < 0.05). | |||
|
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Lactobacillus was decreased by Tigecycline (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
|
Studied Microbe: Verrucomicrobiaceae
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Verrucomicrobiaceae was increased by Tigecycline. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: Bacteroidetes
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bacteroidetes was decreased by Tigecycline. | |||
|
Studied Microbe: Firmicutes
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Firmicutes was decreased by Tigecycline. | |||
|
Studied Microbe: Proteobacteria
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Proteobacteria was increased by Tigecycline. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) | Target Info | Binder | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006 Aug;26(8):1099-110. | |||
| REF 2 | 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). | |||
| REF 3 | Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent). 2006 Apr;19(2):155-61. | |||
| REF 4 | Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. J Clin Pharmacol. 2014 May;54(5):513-9. | |||
| REF 5 | Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother. 2006 Oct;50(10):3375-80. | |||
| REF 6 | Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection. Antimicrob Agents Chemother. 2014 May;58(5):2767-74. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.